<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114672</url>
  </required_header>
  <id_info>
    <org_study_id>10020</org_study_id>
    <nct_id>NCT01114672</nct_id>
  </id_info>
  <brief_title>A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients</brief_title>
  <acronym>CRN11</acronym>
  <official_title>A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winthrop University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Winthrop University Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pruritis (itching) is common in many people with chronic renal failure on hemodialysis.
      There may be many different reasons for the pruritis. Efforts to treat the problem have not
      been very effective.

      Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D
      plays an important role in the skin and is effective in treatment of certain skin conditions
      that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients.

      The objective of the investigators study is to determine the effect of supplementation with
      oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D2 is a fat soluble steroid hormone precursor which must be hydroxylated in the
      liver and kidney respectively to make the active form 1-25-Vitamin D. This active metabolite
      and related analogs have been synthesized and are frequently used in the treatment of
      hyperparathyroidism in patients with chronic kidney disease. However the active metabolite
      may not be back metabolized to the precursor forms which may have functions in other organs
      including the skin. Supplementation of hemodialysis patients with oral vitamin D forms would
      provide a source of precursors for use throughout the body.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Severity of Pruritis</measure>
    <time_frame>Baseline and end of study (up to 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Randomized patients will fill out a survey with questions about the degree and location of their pruritis at baseline and end of study. The total score ranged from 0-21 with 21 being the most severe and zero being the absence of any of the measures of pruritis.
Last observation was carried forward to end of study. A decrease in the Severity of Pruritis score over time indicated an improvement in the severity of pruritis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pruritis</condition>
  <arm_group>
    <arm_group_label>Ergocalciferol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50,000 Units Ergocalciferol</intervention_name>
    <description>50,000 Units oral ergocalciferol to be given once weekly</description>
    <arm_group_label>Ergocalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral placebo once weekly</description>
    <arm_group_label>oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hemodialysis treatment for &gt; 3 months

          2. Subjective complaint of excessive itching

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Failure to provide informed consent

          3. Intact PTH &lt; 70 pg/ml or &gt; 1,000 pg/ml

          4. Serum phosphorus &gt; 7.0

          5. Serum calcium (adjusted for albumin)&gt; 11

          6. Active malignancy

          7. Likelihood of imminent renal transplantation

          8. Current ergocalciferol treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Fishbane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Nephrology, Winthrop Univ Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Schanler, MS, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital, Outpatient Dialysis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winthop Univ Hospital Outpatient Dialysis at Bethpage</name>
      <address>
        <city>Bethpage</city>
        <state>New York</state>
        <zip>11714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop Univ Hospital Outpatient Dialysis</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 15, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2010</firstreceived_date>
  <firstreceived_results_date>January 8, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Winthrop University Hospital</investigator_affiliation>
    <investigator_full_name>Mary Schanler</investigator_full_name>
    <investigator_title>Administrative Dietitian</investigator_title>
  </responsible_party>
  <keyword>Pruritis in hemodialysis patients</keyword>
  <keyword>25-Vitamin D in chronic kidney disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients undergoing maintenance hemodialysis were recruited from two hemodialysis facilities from 8/11/2010 to 8/1/2011.</recruitment_details>
      <pre_assignment_details>Three patients failed the screening process due to exclusion criteria: One patient had PTH&lt;70 pg/mL and two patients had serum phosphorus &gt;7.0 mg/dL.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ergocalciferol</title>
          <description>Patients in the Ergocalciferol Arm/Group received 50,000 international units of oral Ergocalciferol once a week for a study period of 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Oral Placebo</title>
          <description>Patients in the oral placebo Arm/Group received a placebo pill once a week for a period of 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>transplanted</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ergocalciferol</title>
          <description>Patients in the Ergocalciferol Arm/Group received 50,000 international units of oral Ergocalciferol once a week for a study period of 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Oral Placebo</title>
          <description>Patients in the oral placebo Arm/Group received a placebo pill once a week for a period of 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="24"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66.1" spread="14.7"/>
                <measurement group_id="B2" value="66.2" spread="13.7"/>
                <measurement group_id="B3" value="66.2" spread="15.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Pruritis</title>
        <description>Randomized patients will fill out a survey with questions about the degree and location of their pruritis at baseline and end of study. The total score ranged from 0-21 with 21 being the most severe and zero being the absence of any of the measures of pruritis.
Last observation was carried forward to end of study. A decrease in the Severity of Pruritis score over time indicated an improvement in the severity of pruritis.</description>
        <time_frame>Baseline and end of study (up to 12 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Number randomized in each arm 25</population>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol</title>
            <description>Patients in the Ergocalciferol Arm/Group received 50,000 international units of oral Ergocalciferol once a week for a study period of 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>Patients in the oral placebo Arm/Group received a placebo pill once a week for a period of 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Severity of Pruritis</title>
            <description>Randomized patients will fill out a survey with questions about the degree and location of their pruritis at baseline and end of study. The total score ranged from 0-21 with 21 being the most severe and zero being the absence of any of the measures of pruritis.
Last observation was carried forward to end of study. A decrease in the Severity of Pruritis score over time indicated an improvement in the severity of pruritis.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.88" spread="5.15"/>
                  <measurement group_id="O2" value="9.76" spread="5.34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>End of study</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.64" spread="6.14"/>
                  <measurement group_id="O2" value="5.12" spread="4.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <desc>Only serious adverse events were intended to be collected in this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Ergocalciferol</title>
          <description>Patients in the Ergocalciferol Arm/Group received 50,000 international units of oral Ergocalciferol once a week for a study period of 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Oral Placebo</title>
          <description>Patients in the oral placebo Arm/Group received a placebo pill once a week for a period of 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Not related to study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <description>Patient admitted to hospital with gastroparesis. Determined not to be related to study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Not related to study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cirrhosis</sub_title>
                <description>Pre-existing condition</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <description>Not related to study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Not related to study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Not related to study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mary Schanler, Principal Investigator</name_or_title>
      <organization>Winthrop University Hospital</organization>
      <phone>5156639028</phone>
      <email>mschanler@winthrop.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
